Novavax, Inc. (Nasdaq: NVAX), a pioneering player in the protein-based vaccines space with its Matrix-M™ adjuvant, is excited to announce that it will report its second quarter 2023 financial results and operational highlights on Tuesday, August 8, 2023 at 8:30 a.m. EDT. Tune in to this event to learn more about the company’s latest developments and financial performance! A replay of the event will be available shortly after.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined.